2 active not recruiting, 2 withdrawn, 1 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Withdrawn 2 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Platinum-Refractory Primary Peritoneal Carcinoma: new trials by email Literature Review of Platinum-Refractory Primary Peritoneal Carcinoma trials Research Report on Platinum-Refractory Primary Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. TILT-123, pembrolizumab, pegylated liposomal doxorubicin - Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | TILT Biotherapeutics Ltd. | 29 | 2022-05-17 | 2026-05-05 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
Adenoviridae Infections (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Peritoneal Neoplasms (1) · Uterine Cervical Neoplasms (1)
Abdominal Neoplasms (1) · Adnexal Diseases (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Infections (1)
Magnetic Resonance Spectroscopy (3) · Paclitaxel (3) · Taxes (3) · liposomal doxorubicin (3) · Disulfides (2) · Doxorubicin (2) · Immunoglobulin G (2) · Specimen Handling (2) · Topotecan (2) · olaparib (2) · 1-dodecylpyridoxal (1) · ASTX-660 (1) · Bevacizumab (1) · CTLA-4 Antigen (1) · Contrast Media (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (1) · TILT Biotherapeutics Ltd. (1)
United States (4) · Finland (1) · Puerto Rico (1)
Amir A Jazaeri (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Panagiotis A Konstantinopoulos (1)
PMID 38471508, PMID 39506856, PMID 41566775
U10CA180868 (3)